We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer

This study has been terminated.
(Lack of funding)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01407341
First Posted: August 2, 2011
Last Update Posted: February 6, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California
  Purpose
This pilot clinical trial studies beta-tricalcium phosphate bone graft in treating patients undergoing surgery for metastatic spine cancer. A bone graft may help healing and bone growth in patients undergoing surgery for spine cancer

Condition Intervention Phase
Adult Spinal Cord Neoplasm Spinal Bone Metastases Spinal Cord Compression Procedure: musculoskeletal complications management/prevention Procedure: bone graft Procedure: quality-of-life assessment Other: questionnaire administration Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: ChronOS Stability Study: For Metastatic Cancer

Resource links provided by NLM:


Further study details as provided by University of Southern California:

Primary Outcome Measures:
  • Achievement of durable posterolateral fusion [ Time Frame: Within 12 months ]
    Measured from x-ray and/or computed tomography (CT) scans. Standard criteria of determining fusion is visualization of continuous trabeculating bone bridging the transverse processes and facets on AP and lateral x-rays or when there is < 2 degree angular motion and < 2mm of translation on standing flexion and extension radiographs.


Secondary Outcome Measures:
  • Achievement of posterolateral fusion [ Time Frame: Up to 12 months ]
  • Occurrence of subsequent hardware failure [ Time Frame: Every 3 months for 12 months ]
  • Requirement of additional treatment is for instability [ Time Frame: Within 12 months ]
  • First documentation of posterolateral fusion [ Time Frame: Within 12 months ]
  • Occurrence of pain or disability experienced after surgery that is related to spinal metastasis or is a consequence of the resulting treatment [ Time Frame: Every 3 months for 12 months ]

Enrollment: 1
Study Start Date: June 2011
Study Completion Date: August 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Supportive care (ChronOS)
Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
Procedure: musculoskeletal complications management/prevention
Receive beta tricalcium-phosphate bone graft
Other Names:
  • complications management/prevention, musculoskeletal
  • management/prevention, musculoskeletal complications
Procedure: bone graft
Receive beta tricalcium-phosphate bone graft
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Other: questionnaire administration
Ancillary studies

Detailed Description:
OBJECTIVES: I. To determine if Chronos (beta-tricalcium phosphate bone graft) will form a posterolateral fusion mass in patients undergoing fusion surgery for spine cancer within 12 months. II. To evaluate quality of life following the use of ChronOS as measured by (a) pain (or lack of pain) associated with pseudoarthrosis and (b) the need for additional treatment for instability as a result of hardware failure. OUTLINE: Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery. After completion of study treatment, patients are followed up at 1 month and then every 3 months for 1 year.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients undergoing surgery for spinal decompression for tatic spine cancer who require bone substitute for a posterolateral spinal fusion
  • Patients may or may not have posterolateral instrumentation

Exclusion Criteria:

  • Status-post previous fusion with allogeneic bone graft
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01407341


Locations
United States, California
University of Southern California
Los Angeles, California, United States, 90033-0804
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Investigators
Principal Investigator: Thomas Chen University of Southern California
  More Information

Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT01407341     History of Changes
Other Study ID Numbers: 0S-09-12
NCI-2011-01243 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Submitted: July 29, 2011
First Posted: August 2, 2011
Last Update Posted: February 6, 2014
Last Verified: August 2012

Additional relevant MeSH terms:
Spinal Cord Compression
Spinal Cord Neoplasms
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Spinal Cord Injuries
Wounds and Injuries
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms